26 November 2025 - The MHRA has today approved inavolisib (Itovebi) for the treatment of adults with a type of breast cancer called HR positive, HER2 negative breast cancer.

Inavolisib is licensed for adults whose breast cancer has come back, during or soon after hormone therapy, and has spread to other parts of the body. It will be available to patients whose cancer has specific changes in its genes and is not suitable for those who have recently had certain other cancer treatments.

Read UK Government press release